<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87376">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942551</url>
  </required_header>
  <id_info>
    <org_study_id>DK-DT-001</org_study_id>
    <nct_id>NCT01942551</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongkook Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongkook Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two-arm, one-sequence, cross-over study to evaluate the safety and
      pharmacokinetic interaction after oral concomitant administration of tadalafil and
      dutasteride in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of tadalafil</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tadalafil</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of dutasteride</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48, 72, 96, 144, 192, 240, 288, 336 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of dutasteride</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 32, 48, 72, 96, 144, 192, 240, 288, 336 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>tadalafil, dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dutasteride, tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <arm_group_label>tadalafil, dutasteride</arm_group_label>
    <arm_group_label>dutasteride, tadalafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <arm_group_label>tadalafil, dutasteride</arm_group_label>
    <arm_group_label>dutasteride, tadalafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 20 to 29 years 2. Weight 60 kg or more, within 20% of Ideal body weight 3. No
             congenital or chronic diseases, no disease symptoms or findings 4. Eligible according
             to the laboratory results of hematology, blood chemistry and urinalysis 5.
             Voluntarily signed the informed consent form

        Exclusion Criteria:

          -  1. Clinically significant disorders of hepatobiliary system, kidney, neurology,
             respiratory, hemato-oncology, endocrine, dermatology, urology, ophthalmology,
             psychiatry, musculo-skeletal system, immunology, otorhinolaryngology, and
             cardiovascular system 2. Gastrointestinal diseases or surgery which may affect
             absorption of the investigational products 3. hypersensitivity to tadalafil or
             phosphodiesterase type 5 inhibitor, and dutasteride or 5-α reductase inhibitor 4.
             Lactose intolerance 5. SBP ≥ 140 mmHg or &lt; 90 mmHg or DBP ≥ 95 mmHg or &lt; 60 mmHg 6.
             Serum creatinine &gt; ULN 7. History or positive result of drug abuse 8. Drugs which
             induce or inhibit drug metabolism including barbiturates within 1 month 9. Prescribed
             drugs or herbal medicines within 2 weeks, or over-the counter drugs or vitamins
             within 1 week 10. CYP3A4 inhibitors or CYP3A4 inducers within 2 weeks 11. Food
             including grapefruit from Week -1 to final dose 12. Participated and administered the
             investigational products in other clinical trial within 2 months 13. Donated whole
             blood within 2 months or apheresis within 1 month, or transfusion within 1 month 14.
             Plans to donate blood for at least 6 months after final dose of dutasteride 15.
             Scheduled dental treatment and elective surgery from informed consent to post-study
             visit 16. Excessive alcohol consumption (&gt; 21 units/week, 1 unit = 10 g of pure
             alcohol) 17. Smoked more than 10 cigarettes a day for past 3 months 18. Not eligible
             due to other reasons including laboratory results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JaeWoo Kim</last_name>
      <phone>+82-42-280-8618</phone>
      <email>zeusy@cnuh.co.kr</email>
    </contact>
    <investigator>
      <last_name>JaeWoo Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 15, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
